Detalles de la búsqueda
1.
Personalizing age of gastric cancer screening based on comorbidity in China: Model estimates of benefits, affordability and cost-effectiveness optimization.
Prev Med
; 179: 107851, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38191061
2.
Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study.
BMC Med
; 21(1): 277, 2023 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37501074
3.
Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.
Gynecol Oncol
; 168: 17-22, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36368128
4.
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
PLoS One
; 18(4): e0279786, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37053300
5.
Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States.
Clin Ther
; 45(10): 965-972, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37537015
6.
Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review.
Front Pharmacol
; 13: 860109, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35496294
7.
Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer.
Front Pharmacol
; 13: 881787, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35712723
8.
Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Front Pharmacol
; 13: 778505, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35222020
9.
Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis.
Clin Rheumatol
; 41(1): 63-73, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34373933
10.
Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.
Front Public Health
; 10: 955120, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36033760
11.
Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.
Pharmacoeconomics
; 40(7): 725-737, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35701687
12.
Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
Adv Ther
; 38(12): 5710-5720, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34693504
13.
First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.
Adv Ther
; 38(5): 2447-2457, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33821431
14.
Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population.
Adv Ther
; 38(5): 2571-2585, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33837917
15.
Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer.
Adv Ther
; 38(7): 3962-3972, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34100243
16.
Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
Adv Ther
; 38(8): 4354-4365, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34241780
17.
Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy.
Front Oncol
; 11: 743765, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34858820
18.
Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.
Adv Ther
; 38(6): 3399-3408, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019245
Resultados
1 -
18
de 18
1
Próxima >
>>